Tags

Type your tag names separated by a space and hit enter

Outcomes in 45 patients with statin-associated myopathy.
Arch Intern Med. 2005 Dec 12-26; 165(22):2671-6.AI

Abstract

BACKGROUND

Published studies regarding statin-associated myopathy may describe more dramatic patient presentations, potentially leading to inaccurate characterization of the condition. Furthermore, long-term outcomes and responses to statin rechallenge in patients with statin-associated myopathy are largely unknown.

METHODS

The University of Wisconsin Hospital and Clinics Medical Informatics Department identified 437 patients with International Classification of Diseases, Ninth Revision codes potentially representing cases of statin-associated myopathy from more than 13 years of inpatient and outpatient data; 45 of these individuals were diagnosed as having statin-associated myopathy. Using a standardized form, 2 researchers abstracted all the case records to define the clinical course of statin-induced myopathy.

RESULTS

The mean (SD) duration of statin therapy before symptom onset was 6.3 (9.8) months. Resolution of muscle pain occurred a mean (SD) of 2.3 (3.0) months after discontinuation of statin therapy. Six patients (13%) were hospitalized for the management of rhabdomyolysis; 2 had reversible renal dysfunction, and 1 with preexisting renal insufficiency subsequently began lifelong dialysis. Hospitalized patients developed myopathy more quickly after initiating statin therapy (1.3 vs 7.1 months; P = .048) and were more likely to be taking concomitant medications known to increase the risk of statin-associated myopathy (P = .03). Thirty-seven patients received another statin after an episode of statin-associated myopathy; 21 (57%) reported recurrent muscle pain, whereas 16 (43%) tolerated other statins without recurrent symptoms.

CONCLUSIONS

Patients with statin-associated myopathy experienced full resolution of muscle pain on cessation of statin therapy. Although no deaths occurred, 13% of the patients required hospitalization for rhabdomyolysis. Recurrent muscle pain was common on statin rechallenge.

Authors+Show Affiliations

Rheumatology Section, University of Wisconsin Medical School, H6/363 Clinical Science Center, 600 Highland Avenue, Madison, WI 53792, USA. keh@medicine.wisc.eduNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16344427

Citation

Hansen, Karen E., et al. "Outcomes in 45 Patients With Statin-associated Myopathy." Archives of Internal Medicine, vol. 165, no. 22, 2005, pp. 2671-6.
Hansen KE, Hildebrand JP, Ferguson EE, et al. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med. 2005;165(22):2671-6.
Hansen, K. E., Hildebrand, J. P., Ferguson, E. E., & Stein, J. H. (2005). Outcomes in 45 patients with statin-associated myopathy. Archives of Internal Medicine, 165(22), 2671-6.
Hansen KE, et al. Outcomes in 45 Patients With Statin-associated Myopathy. Arch Intern Med. 2005 Dec 12-26;165(22):2671-6. PubMed PMID: 16344427.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Outcomes in 45 patients with statin-associated myopathy. AU - Hansen,Karen E, AU - Hildebrand,Julie P, AU - Ferguson,Edwin E, AU - Stein,James H, PY - 2005/12/14/pubmed PY - 2006/1/13/medline PY - 2005/12/14/entrez SP - 2671 EP - 6 JF - Archives of internal medicine JO - Arch. Intern. Med. VL - 165 IS - 22 N2 - BACKGROUND: Published studies regarding statin-associated myopathy may describe more dramatic patient presentations, potentially leading to inaccurate characterization of the condition. Furthermore, long-term outcomes and responses to statin rechallenge in patients with statin-associated myopathy are largely unknown. METHODS: The University of Wisconsin Hospital and Clinics Medical Informatics Department identified 437 patients with International Classification of Diseases, Ninth Revision codes potentially representing cases of statin-associated myopathy from more than 13 years of inpatient and outpatient data; 45 of these individuals were diagnosed as having statin-associated myopathy. Using a standardized form, 2 researchers abstracted all the case records to define the clinical course of statin-induced myopathy. RESULTS: The mean (SD) duration of statin therapy before symptom onset was 6.3 (9.8) months. Resolution of muscle pain occurred a mean (SD) of 2.3 (3.0) months after discontinuation of statin therapy. Six patients (13%) were hospitalized for the management of rhabdomyolysis; 2 had reversible renal dysfunction, and 1 with preexisting renal insufficiency subsequently began lifelong dialysis. Hospitalized patients developed myopathy more quickly after initiating statin therapy (1.3 vs 7.1 months; P = .048) and were more likely to be taking concomitant medications known to increase the risk of statin-associated myopathy (P = .03). Thirty-seven patients received another statin after an episode of statin-associated myopathy; 21 (57%) reported recurrent muscle pain, whereas 16 (43%) tolerated other statins without recurrent symptoms. CONCLUSIONS: Patients with statin-associated myopathy experienced full resolution of muscle pain on cessation of statin therapy. Although no deaths occurred, 13% of the patients required hospitalization for rhabdomyolysis. Recurrent muscle pain was common on statin rechallenge. SN - 0003-9926 UR - https://www.unboundmedicine.com/medline/citation/16344427/Outcomes_in_45_patients_with_statin_associated_myopathy_ L2 - https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/archinte.165.22.2671 DB - PRIME DP - Unbound Medicine ER -